IP Library Granted Patent US 7,794,935
Granted Patent B2
US 7,794,935 · App. 11/442,525 · Granted Sep 14, 2010

Reverse transcriptase compositions for flap-mediated detection of a target nucleic acid sequence

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,794,935
App. No.
11/442,525
Granted
Sep 14, 2010
Kind
B2
Abstract

The invention relates to compositions for generating a signal indicative of the presence of a target nucleic acid in a sample. The compositions include a reverse transcriptase, a nuclease, an upstream primer and downstream probe.

Claims (47)

1. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid;

(iii) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and, wherein said 5′ region is not complementary to said target nucleic acid;

(iv) a reverse transcriptase; and

(v) a cleavage means.

2. The composition of claim 1 , wherein said cleavage means comprises a 5′ nuclease.

3. The composition of claim 2 , wherein said 5′ nuclease is a FEN-1 nuclease.

4. The composition of claim 3 , wherein said FEN-1 nuclease is a flap specific nuclease.

5. The composition of claim 3 , wherein said FEN-1 nuclease is thermostable.

6. The composition of claim 1 , wherein said reverse transcriptase is thermostable.

7. The composition of claim 1 , wherein the 3′ nucleotide of said second oligonucleotide has a blocking group.

8. The composition of claim 1 , wherein the second oligonucleotide comprises at least one labeled moiety capable of providing a signal.

9. The composition of claim 1 , wherein the second oligonucleotide comprises a pair of interactive signal generating labeled moieties.

10. The composition of claim 9 , wherein said pair of interactive signal generating moieties comprises a quencher moiety and a fluorescent moiety.

11. The composition of claim 10 , wherein at least one member of the pair of interactive signal generating labeled moieties is operatively coupled to the 5′ region of the second oligonucleotide.

12. The composition of claim 8 , wherein the at least one labeled moiety is operatively coupled to the 5′ region of the second oligonucleotide.

13. A kit comprising a composition of claim 1 and packaging materials therefore.

14. The kit of claim 13 , wherein said cleavage means comprises a 5′ nuclease.

15. The kit of claim 14 , wherein said 5′ nuclease is a FEN-1 nuclease.

16. The kit of claim 13 , wherein the 3′ nucleotide of said second oligonucleotide has a blocking group.

17. The kit of claim 13 , wherein the second oligonucleotide comprises at least one labeled moiety capable of providing a signal.

18. The kit of claim 13 , wherein the second oligonucleotide comprises a pair of interactive signal generating labeled moieties.

19. The kit of claim 18 , wherein said pair of interactive signal generating moieties comprises a quencher moiety and a fluorescent moiety.

20. The kit of claim 18 , wherein at least one member of the pair of interactive signal generating labeled moieties is operatively coupled to the 5′ flap of the second oligonucleotide.

21. The kit of claim 17 , wherein the at least one labeled moiety is operatively coupled to the 5′ flap of the second oligonucleotide.

22. A composition comprising:

(i) a target nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said target nucleic acid;

(iii) a second oligonucleotide corresponding to said target nucleic acid, said second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target nucleic acid and wherein said 5′ region is at least partially complementary to a region that may be upstream of, downstream of, or comprise said first region of said target nucleic acid;

(iv) a reverse transcriptase; and

(v) a cleavage means.

23. A kit comprising the composition of claim 22 and packaging materials therefore.

24. A composition comprising:

(i) a template nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said target template nucleic acid;

(iii) a second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said target template nucleic acid and wherein said 5′ region is not complementary to said target template nucleic acid;

(iv) a reverse transcriptase; and

(v) a cleavage means.

25. A kit comprising the composition of claim 24 and packaging materials therefore.

26. A composition comprising:

(i) a template nucleic acid, which comprises in 3′ to 5′ order a first region, an extension region, and a second region;

(ii) a first oligonucleotide that is at least partially complementary to said first region of said template nucleic acid;

(iii) a second oligonucleotide corresponding to said template nucleic acid, said second oligonucleotide comprising a 5′ region and a 3′ region, wherein said 3′ region is at least partially complementary to said second region of said template nucleic acid and wherein said 5′ region is at least partially complementary to a region that may be upstream of, downstream of, or comprise said first region of said template nucleic acid;

(iv) a reverse transcriptase; and

(v) a cleavage means.

27. A kit comprising the composition of claim 26 and packaging materials therefore.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →